Brief: NLS Pharmaceutics Announces Issuance of Canadian Patent Covering Formulation Mazindol CR
29/03/2021 13:56
March 29 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS ANNOUNCES ISSUANCE OF CANADIAN PATENT
COVERING
ITS NOVEL FORMULATION OF CONTROLLED-RELEASE MAZINDOL (MAZINDOL
CR)
Source text for Eikon: ID:nPn1c0xFla
Further company coverage: NLSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing